Drug profile · INN
clidinium bromide
QUARZAN
clidinium bromide (QUARZAN) is a muscarinic acetylcholine receptor m3 antagonist. Route of administration: oral. Current US regulatory status: approved.
Drug details — clidinium bromide
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 2
- Data quality
- 0.84
Quick answer
clidinium bromide (QUARZAN) is a muscarinic acetylcholine receptor m3 antagonist. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Muscarinic acetylcholine receptor M3 antagonist
Primary target: Muscarinic acetylcholine receptor M1
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is clidinium bromide?
clidinium bromide (QUARZAN) is a muscarinic acetylcholine receptor m3 antagonist. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for clidinium bromide?
QUARZAN is a marketed brand name for clidinium bromide. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of clidinium bromide?
clidinium bromide has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.